Preliminary communicationDepression and eating disorders: Treatment and course
Introduction
Eating disorders (EDs) have high rates of comorbidity with other mental illnesses, especially major depressive disorder (MDD). Multiple studies indicate that MDD is the most common comorbid diagnosis in patients with EDs (Herzog et al., 1992, Fichter and Quadflieg, 2004, Kaye et al., 2008); the American Psychiatric Association has reported that lifetime rates of MDD in individuals with EDs range between 50% and 75% (American Psychiatric Association Workgroup on Eating Disorders, 2006); and MDD comorbid with EDs has been associated with worse ED outcome (Lowe et al., 2001, Berkman et al., 2007), including high rates of suicide attempts (Franko et al., 2004, Bulik et al., 2008, Forcano et al., 2009) and suicide-related mortality (Crow et al., 2009).
Despite the overlap between EDs and depression, FDA-approved antidepressants have not shown promise in alleviating depression in patients with EDs. Although fluoxetine has been approved to treat bulimia nervosa (BN), the drug has shown mixed efficacy in reducing MDD in this group (Pope et al., 1983, Fichter et al., 1991, Fluoxetine Bulimia Nervosa Collaborative Study Group, 1992, Goldbloom and Olmsted, 1993, Beumont et al., 1997, Walsh et al., 1997, Romano et al., 2002). Moreover, antidepressant treatment does not result in improvement in depressive symptomatology in anorexia nervosa (AN) treatment trials (Attia et al., 1998, Walsh et al., 2006). In view of the high rates of suicide and treatment resistance in individuals with comorbid MDD and ED, characterizing the course of MDD and identifying predictors of MDD recovery and relapse in individuals with EDs are important avenues for research.
In 1987 we initiated a prospective longitudinal study of treatment-seeking women with AN and BN to map the course and outcome of EDs. We have previously examined psychiatric comorbidity and found high rates of MDD in this sample (Herzog et al., 1992). Depression severity was associated with increased risk for attempted suicide in AN participants (Franko et al., 2004). By a median of 9 years of follow-up, 11 women had died (Keel et al., 2003). In this study we address the following questions about MDD: (a) What is the course of MDD?; (b) What variables are associated with recovery from and relapse to MDD?; and (c) What types of antidepressant medications do women with EDs receive for MDD and are these treatments adequate by current standards? We hypothesized that the course of MDD would be longer if there was no recovery from ED. Likewise, we expected that women who received antidepressants would be more likely to recover from MDD, even if their ED did not significantly improve.
Section snippets
Participants
Five hundred and fifty-four women who sought treatment at Massachusetts General Hospital and other treatment centers in the Boston area between 1987 and 1990 were screened to determine whether they met criteria for AN or BN set forth in the 3rd Revised Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R; American Psychiatric Association, 1987). Two hundred and twenty-five women originally agreed to participate in the study, and in 1991, 21 additional participants
Results
Of the 145 patients with MDD included in the analysis, 102 (70%) recovered from MDD over the course of the study, but 66 (65%) of these 102 patients subsequently relapsed to MDD. The mean and median follow-up time for the analysis population was 8.8 and 10.0 years, respectively (range = 3 months–12 years). Time from MDD onset to recovery (8 weeks–8.7 years) and time from MDD recovery to relapse (1 week–5.2 years) varied greatly, as did time from study entry to new onset of MDD (1 week–4.3 years) for
Discussion
To our knowledge, this is the first prospective investigation of the course of MDD in an ED sample, derived from the largest and longest prospective, naturalistic longitudinal follow-up of women with EDs. Consistent with previous reports of MDD in ED samples (Brewerton et al., 1995, Godart et al., 2004, Fernandez-Aranda et al., 2007, Herzog and Eddy, 2007), we found that 59% of the 246 patients recruited had one or more episodes of depression, a prevalence much greater than the 15% or so that
Role of funding source
This work was supported by the National Institute of Mental Health grant 5R01 MH 38333 05 (DBH) and the Rubenstein Charitable Foundation, Boston MA. Sponsors had no further role in the study design, collection, analysis and interpretation of data, writing of the report, and the decision to submit the paper for publication.
Conflict of interest
Dr. Mischoulon has received research support from Laxdale (Amarin), Nordic Naturals, Ganeden, and SwissMedica. He has served as a consultant to Bristol-Meyers-Squibb Company. He has received speaking honoraria from Pamlab, Virbac, and Nordic Naturals. He has received writing honoraria from Pamlab. He has received royalties from Back Bay Scientific for PMS Escape, and royalties from Lippincott Williams & Wilkins, for textbook “Natural Medications for Psychiatric Disorders: Considering the
Acknowledgments
None to report.
References (38)
- et al.
Suicide attempts in bulimia nervosa: personality and psychopathological correlates
European Psychiatry
(2009) - et al.
Psychiatric comorbidity in treatment-seeking anorexics and bulimics
Journal of the American Academy of Child & Adolescent Psychiatry
(1992) - et al.
Recovery and relapse in anorexia and bulimia nervosa: a 7.5-year follow-up study
Journal of the American Academy of Child & Adolescent Psychiatry
(1999) Diagnostic and Statistical Manual of Mental Disorders
(1987)Diagnostic and Statistical Manual of Mental Disorders
(1994)Practice guideline for the treatment of patients with eating disorders (revision)
American Journal of Psychiatry
(2006)- et al.
Does fluoxetine augment the impatient treatment of anorexia nervosa?
American Journal of Psychiatry
(1998) - et al.
An inventory for measuring depression
Archives of General Psychiatry
(1961) - et al.
The process of recovering from anorexia nervosa
Journal of the American Academy of Psychoanalysis
(1989) - et al.
Outcomes of eating disorders: a systematic review of the literature
International Journal of Eating Disorders
(2007)
Intensive nutritional counseling in bulimia nervosa: a role for supplementation with fluoxetine?
Australian and New Zealand Journal of Psychiatry
Comorbidity of axis I psychiatric disorders in bulimia nervosa
Journal of Clinical Psychiatry
Suicide attempts in anorexia nervosa
Psychosomatic Medicine
Increased mortality in bulimia nervosa and other eating disorders
American Journal of Psychiatry
Symptom profile of major depressive disorder in women with eating disorders
Australian and New Zealand Journal of Psychiatry
Twelve-year course and outcome of bulimia nervosa
Psychological Medicine
Fluoxetine versus placebo: a double-blind study with bulimic in patients undergoing intensive psychotherapy
Pharmacopsychiatry
Fluoxetine in the treatment of bulimia nervosa
Archives of General Psychiatry
What predicts suicide attempts in women with eating disorders?
Psychological Medicine
Cited by (105)
Which dimensions of emotion dysregulation predict the onset and persistence of eating disorder behaviours? A prospective study
2022, Journal of Affective DisordersUnderstanding and Treatment of Eating Disorders in Children and Adolescents
2022, Comprehensive Clinical Psychology, Second EditionGhrelin mediated regulation of neurosynaptic transmitters in depressive disorders
2022, Current Research in Pharmacology and Drug DiscoveryUsing shape and weight overvaluation to empirically differentiate severity of other specified feeding or eating disorder
2021, Journal of Affective DisordersAssociations between eating disorder symptoms, employment status, and occupational functioning among female veterans
2021, Eating BehaviorsCitation Excerpt :In examining associations between EDs and work-related variables, it is important to consider potential mediators. High rates of depression have been found among those with EDs (Buchholz et al., 2018; Godart et al., 2015; Mischoulon et al., 2011), and depression is strongly associated with employment status and occupational functioning (Hamilton et al., 2015; Lagerveld et al., 2010; Lerner et al., 2010; Lerner & Henke, 2008; Smith et al., 2017). A review of depression and multiple functioning domains, including occupational functioning, found that depression has an equal or worse impact on functioning compared to other chronic conditions (McKnight & Kashdan, 2009).
The shifting perspectives study protocol: Cognitive remediation therapy as an adjunctive treatment to family based treatment for adolescents with anorexia nervosa
2021, Contemporary Clinical TrialsCitation Excerpt :Siblings currently living with the participant are asked to attend at least the first four sessions of treatment. Epidemiological data indicate anxiety, depression, and obsessive compulsive disorder are common among individuals with AN [42–46]; in order to increase external validity, individuals with these co-morbidities will be included. Likewise, we will not exclude participants for the use of medication, with the exception of atypical antipsychotics (e.g., olanzapine).